Difference between revisions of "Comment Resolutions"
Jump to navigation
Jump to search
(Deleted maintenance CTA clinically feasible Profile 2023-02-16) |
m |
||
Line 29: | Line 29: | ||
| [[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf| CT Atherosclerosis 2023-03-28]] | | [[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf| CT Atherosclerosis 2023-03-28]] | ||
| Clinically Feasible | | Clinically Feasible | ||
− | | | + | | 2023.03.07 |
| [[Media:CTA Profile Clinically Feasible Comment Resolutions.2023Mar28.pdf|Clinically Feasible Comment Resolutions 2023-03-28]] | | [[Media:CTA Profile Clinically Feasible Comment Resolutions.2023Mar28.pdf|Clinically Feasible Comment Resolutions 2023-03-28]] | ||
|- | |- |
Revision as of 17:25, 4 April 2023
Comments received during Public Comment, Clinically Feasible (formerly Technical) Confirmation, or during a Profile ballot, are reviewed by the originating Biomarker Committee.
Per the QIBA Process, committees record how each collected comment was resolved and those resolutions are posted here.